435 related articles for article (PubMed ID: 22409666)
1. Modern phenotypic drug discovery is a viable, neoclassic pharma strategy.
Lee JA; Uhlik MT; Moxham CM; Tomandl D; Sall DJ
J Med Chem; 2012 May; 55(10):4527-38. PubMed ID: 22409666
[No Abstract] [Full Text] [Related]
2. Big pharma screening collections: more of the same or unique libraries? The AstraZeneca-Bayer Pharma AG case.
Kogej T; Blomberg N; Greasley PJ; Mundt S; Vainio MJ; Schamberger J; Schmidt G; Hüser J
Drug Discov Today; 2013 Oct; 18(19-20):1014-24. PubMed ID: 23127858
[TBL] [Abstract][Full Text] [Related]
3. The long march of antisense.
Jones D
Nat Rev Drug Discov; 2011 Jun; 10(6):401-2. PubMed ID: 21629279
[No Abstract] [Full Text] [Related]
4. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
Graul AI; Revel L; Rosa E; Cruces E
Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
[TBL] [Abstract][Full Text] [Related]
5. Fragment-Based Drug Discovery--CHI's Fourth Annual Meeting. 6-7 April 2009, San Diego, CA, USA.
Seneci P
IDrugs; 2009 Jun; 12(6):353-7. PubMed ID: 19517314
[No Abstract] [Full Text] [Related]
6. Charting, navigating, and populating natural product chemical space for drug discovery.
Lachance H; Wetzel S; Kumar K; Waldmann H
J Med Chem; 2012 Jul; 55(13):5989-6001. PubMed ID: 22537178
[TBL] [Abstract][Full Text] [Related]
7. Menelas Pangalos. Interview by Asher Mullard.
Mullard A
Nat Rev Drug Discov; 2013 Jun; 12(6):418. PubMed ID: 23722338
[No Abstract] [Full Text] [Related]
8. A novel imaging-based high-throughput screening approach to anti-angiogenic drug discovery.
Evensen L; Micklem DR; Link W; Lorens JB
Cytometry A; 2010 Jan; 77(1):41-51. PubMed ID: 19834964
[TBL] [Abstract][Full Text] [Related]
9. Could pharma open its drug freezers?
Mullard A
Nat Rev Drug Discov; 2011 Jun; 10(6):399-400. PubMed ID: 21629278
[No Abstract] [Full Text] [Related]
10. Jay Bradner.
Nat Rev Drug Discov; 2017 Mar; 16(4):232-233. PubMed ID: 28356589
[No Abstract] [Full Text] [Related]
11. Neoclassic drug discovery: the case for lead generation using phenotypic and functional approaches.
Lee JA; Berg EL
J Biomol Screen; 2013 Dec; 18(10):1143-55. PubMed ID: 24080259
[TBL] [Abstract][Full Text] [Related]
12. Society for Biomolecular Sciences--15th Annual Conference. Bioassay and technology innovation: 15 years of shaping drug discovery. 26-30 April 2009, Lille, France.
Napper AD
IDrugs; 2009 Jun; 12(6):363-5. PubMed ID: 19517316
[No Abstract] [Full Text] [Related]
13. [Advance in the research and discovery of novel drugs based on chemogenomics].
He BK; Ma ZC; Wang YG; Gao Y
Yao Xue Xue Bao; 2008 Nov; 43(11):1077-81. PubMed ID: 19239023
[TBL] [Abstract][Full Text] [Related]
14. Translational regenerative medicine research: essential to discovery and outcome.
Mason C; Dunnill P
Regen Med; 2007 May; 2(3):227-9. PubMed ID: 17511558
[No Abstract] [Full Text] [Related]
15. Novel trends in high-throughput screening.
Mayr LM; Bojanic D
Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
[TBL] [Abstract][Full Text] [Related]
16. Postgenomic strategies in antibacterial drug discovery.
Brötz-Oesterhelt H; Sass P
Future Microbiol; 2010 Oct; 5(10):1553-79. PubMed ID: 21073314
[TBL] [Abstract][Full Text] [Related]
17. Affairs of the Heart: Innovation in Cardiovascular Research and Development.
Honig P; Terzic A
Clin Pharmacol Ther; 2017 Aug; 102(2):162-168. PubMed ID: 28718903
[TBL] [Abstract][Full Text] [Related]
18. Eyes on new product development.
Novack GD
J Ocul Pharmacol Ther; 2014 Jun; 30(5):371-2. PubMed ID: 24897062
[No Abstract] [Full Text] [Related]
19. Improving lead generation success through integrated methods: transcending 'drug discovery by numbers'.
Campbell JB
IDrugs; 2010 Dec; 13(12):874-9. PubMed ID: 21154146
[TBL] [Abstract][Full Text] [Related]
20. Virtual drug discovery with the rise of Chinese CROs.
Zhang MQ
Drug Discov Today; 2010 Sep; 15(17-18):693-7. PubMed ID: 20685343
[No Abstract] [Full Text] [Related]
[Next] [New Search]
